India orders new drug-making standards after overseas deaths

Posted on:
Key Points

Indian pharmaceutical companies must meet new manufacturing standards this year, according to a government notification released on Saturday, although small companies have asked for a delay, citing their debt load...

Jolted by a string of overseas deaths linked to Indian-made drugs since 2022, Prime Minister Narendra Modi's government has stepped up scrutiny of pharmaceutical factories to clean up the image of the $50 billion industry...

"The manufacturer must assume responsibility for the quality of the pharmaceutical products to ensure that they are fit for their intended use, comply with the requirements of the licence and do not place patients at risk due to inadequate safety, quality or efficacy," said the notification, dated Dec. 28...

Companies must market a finished product only after getting "satisfactory results" on tests of the ingredients and retain a sufficient quantity of the samples of intermediate and final products to allow repeated testing or verification of a batch, it says.. The health ministry said in August that inspections of 162 drug factories since December 2022 found an "absence of testing of incoming raw materials"..

You might be interested in

India mandates new drug manufacturing standards after multiple overseas deaths

06, Jan, 24

WHO and other health authorities had linked Indian cough syrups to the deaths of at least 141 children in Gambia, Uzbekistan and Cameroon.

India rubBIShes China factories' quality certification applications

23, Nov, 23

These firms have now written to the government to seek certification for manufacturing units in other Asian nations, a senior government official said. But the government is reluctant to certify factories located even in some Asean countries with which it has a free-trade pact.

Manufacturing sector embraces AI; 54% of firms implement Artificial Intelligence: PwC report

20, Jun, 23

India's manufacturing sector is embracing digital transformation with an adoption rate of 54% for analytics and AI. Despite challenges such as supply chain disruption and geopolitical uncertainties, government initiatives such as 'Make in India' have created a favourable environment for the sector.

India drugs regulator orders quality checks on cough syrup ingredient

08, Dec, 23

India's drugs regulator has ordered that the source and quality of an ingredient used to make cough syrups be checked and verified as a "top priority", in the wake of the deaths of at least 141 children globally.

Launch 'PLI Plus' initiative; focus on new product development to boost mfg: GTRI to govt

23, Apr, 23

The government should consider launching a 'PLI Plus' scheme with focus on development of new products, industrial designs and enhancing productivity with a view to boost domestic manufacturing, economic think tank GTRI said on Sunday.

‘India is well within its right to ensure quality’

07, Apr, 23

Can take action against dumping of poor-quality goods, a govt official said

'Lack of therapeutic justification' — govt bans 14 combination drugs used to treat common ailments

08, Jun, 23

These were a part of 344 fixed dose combinations prohibited for sale by Union Health Ministry in 2016 but the makers of 15 challenged the decision in Delhi High Court.

Reporting faulty manufacture to annual audits: How govt wants drugmakers to improve quality

26, Sep, 23

Nearly 80 percent of small and medium drug manufacturing units in India do not follow good manufacturing practices (GMP) requirements, according to government estimates.

India makes cough syrup testing mandatory for exports

23, May, 23

The move comes after some Indian cough syrups were linked to deaths in The Gambia and Uzbekistan.

India to mark 10 Oct as Good Manufacturing Practice Day

08, Oct, 23

GMP rules are the backbone of pharmaceutical manufacturing operations and help manufacturers prevent non-compliance